Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433834 · ClinicalTrials.gov registry record · Phase 2
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT02433834: Completed Phase 2 study, sponsored by Pearl Therapeutics.
NCT02433834 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 248 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02433834, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Primary Outcome
Forced Expiratory Volume in 1 second (FEV1) within 3 hours post-dosing on Day 15
Interventions
- DRUG Placebo
- DRUG Glycopyrronium MDI
- DRUG Serevent Diskus 50 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2016-03-26 |
| Phase | Phase 2 |
What the finished NCT02433834 record still lists
NCT02433834 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02433834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02433834 about?
NCT02433834 is a clinical study titled "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma". A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label Serevent Diskus in Adult Subjects Wit...
What is the current status of trial NCT02433834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2015-05-27. Estimated completion is 2016-03-26.
What interventions are being tested in trial NCT02433834?
The interventions under investigation include: Placebo (DRUG), Glycopyrronium MDI (DRUG), Serevent Diskus 50 μg (DRUG).
Who is sponsoring clinical trial NCT02433834?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02433834's enrollment target sits among peer trials
248 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI